Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1966 1
1971 3
1972 4
1974 3
1975 2
1976 1
1977 1
1978 1
1981 3
1982 1
1983 1
1984 6
1985 3
1986 1
1987 3
1988 5
1989 3
1990 4
1991 4
1992 2
1993 2
1994 5
1995 1
1996 4
1997 4
1998 3
1999 2
2000 4
2001 7
2002 9
2003 2
2004 9
2005 6
2006 11
2007 10
2008 10
2009 9
2010 13
2011 16
2012 14
2013 16
2014 16
2015 16
2016 26
2017 16
2018 17
2019 23
2020 13
2021 24
2022 25
2023 26
2024 31
2025 37
2026 29

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

461 results

Results by year

Filters applied: . Clear all
Page 1
World Association for Bronchology and Interventional Pulmonology (WABIP) guidelines on airway stenting for malignant central airway obstruction.
Chaddha U, Agrawal A, Kurman J, Ortiz-Comino R, Dutau H, Freitag L, Trisolini R, Dooms C, Zuccatosta L, Gasparini S, Herth F, Saka H, Lee P, Fielding D, Oki M, Rosell A, Murgu S. Chaddha U, et al. Among authors: oki m. Respirology. 2024 Jul;29(7):563-573. doi: 10.1111/resp.14764. Epub 2024 May 29. Respirology. 2024. PMID: 38812262 Free article. Review.
World Association for Bronchology and Interventional Pulmonology (WABIP) Guidelines on Airway Stenting for Benign Central Airway Obstruction.
Chaddha U, Agrawal A, Murgu S, Ghori U, Trias-Sabria P, Ortiz-Comino R, Dutau H, Freitag L, Gasparini S, Lee P, Dooms C, Trisolini R, Madariaga MLL, Li S, Zuccatosta L, Herth F, Saka H, Fielding D, Oki M, Rosell A. Chaddha U, et al. Among authors: oki m. Respirology. 2025 Jul;30(7):587-604. doi: 10.1111/resp.70068. Epub 2025 Jun 27. Respirology. 2025. PMID: 40575842
Response.
Oki M, Saka H. Oki M, et al. Chest. 2016 Oct;150(4):985-986. doi: 10.1016/j.chest.2015.10.025. Chest. 2016. PMID: 27719821 No abstract available.
J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan.
Miyauchi E, Nishio M, Ohashi K, Osoegawa A, Kikuchi E, Kimura H, Goto Y, Shimizu J, Yoshioka H, Yoshino I, Misumi T, Katakami N, Oki M, Kijima T, Chikamori K, Nishino K, Kobayashi Y, Miwa A, Tanaka M, Gemma A. Miyauchi E, et al. Among authors: oki m. JTO Clin Res Rep. 2024 Dec 18;6(3):100783. doi: 10.1016/j.jtocrr.2024.100783. eCollection 2025 Mar. JTO Clin Res Rep. 2024. PMID: 39990134 Free PMC article.
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, Okamoto T, Akamatsu H, Oki M, Sato Y, Tobino K, Ikeda S, Mori M, Mimura C, Maeno K, Miura S, Harada T, Nishimura K, Hiraoka M, Kenmotsu H, Fujimoto J, Shimokawa M, Yamamoto N, Nakagawa K. Sakamoto T, et al. Among authors: oki m. JAMA Netw Open. 2023 Dec 1;6(12):e2347700. doi: 10.1001/jamanetworkopen.2023.47700. JAMA Netw Open. 2023. PMID: 38100106 Free PMC article.
Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study.
Hata A, Ninomaru T, Okada H, Kogure Y, Oki M, Katakami N, Kijima T, Yokoyama T, Matsumoto H, Sato Y, Kato T, Sugawara S, Sawada T, Yoshimura K, Seto T, Nakagawa K, Okamoto I, Yamamoto N; West Japan Oncology Group. Hata A, et al. Among authors: oki m. Lancet Oncol. 2025 Nov;26(11):1432-1442. doi: 10.1016/S1470-2045(25)00462-0. Epub 2025 Oct 11. Lancet Oncol. 2025. PMID: 41082893 Clinical Trial.
Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC.
Kitazono S, Ono A, Kawamura T, Hataji O, Tanaka H, Matsumoto S, Watanabe N, Nagashima H, Oki M, Takahashi M, Anazawa T, Shirai T, Yamashita A, Wortman-Vayn H, Bhattacharya A, Agrawal T, Baig M, Knoblauch RE, Hayashi H. Kitazono S, et al. Among authors: oki m. Cancer Sci. 2025 Nov;116(11):3139-3148. doi: 10.1111/cas.70180. Epub 2025 Sep 8. Cancer Sci. 2025. PMID: 40922529 Free PMC article. Clinical Trial.
Response.
Oki M, Saka H. Oki M, et al. Chest. 2015 Oct;148(4):e130. doi: 10.1378/chest.15-1457. Chest. 2015. PMID: 26437825 No abstract available.
Platinum plus etoposide with durvalumab for extensive-stage small-cell lung cancer with untreated brain metastases: a multicenter, single-arm phase II trial (LOGiK2001, SPEED).
Shiraishi Y, Shimose T, Tsuchiya-Kawano Y, Ishii H, Mizuno K, Toi Y, Daga H, Ito K, Iyama S, Taniguchi H, Morinaga R, Harada T, Inoue H, Misumi Y, Naoki K, Tobino K, Izumi M, Omori S, Tsumura S, Yamanaka Y, Sakata Y, Miura S, Mizutani H, Oki M, Iwama E, Otsubo K, Okamoto I. Shiraishi Y, et al. Among authors: oki m. ESMO Open. 2025 Jul;10(7):105325. doi: 10.1016/j.esmoop.2025.105325. Epub 2025 Jul 3. ESMO Open. 2025. PMID: 40614659 Free PMC article. Clinical Trial.
461 results